Regarding the use of HDAC, which is approved for cutaneous T-cell lymphoma treatment, Beloueche-Babari et al. (85) showed that HDAC inhibition led to an increase in de novo phosphocholine synthesis that was accompanied by ChoKα expression in colon and prostate carcinoma cells in vitro and in vivo (85). This evidence concerns the gene HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma.